Bidirectional effectors of a group I intron ribozyme from Pneumocystis carinii.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The L-arginine acts stereoselectively on the Pc1.LSU nuclear group I intron of Pneumocystis carinii, competitively inhibiting the first step of the splicing reaction and stimulating the second step. A number of arginine-related compounds are more potent than L-arginine as stimulators and inhibitors. The most potent peptides tested are 10,000 times as effective as L-arginine in inhibiting ribozyme activity, and nearly 400 times as effective as stimulators. This phenomenon indicates that ribozymes, like protein enzymes, can interact with non-substrate low molecular weight compounds, and that non-nucleic acid agents might be developed as drugs acting on RNA targets.

Original languageEnglish (US)
JournalThe Journal of eukaryotic microbiology
Volume41
Issue number5
StatePublished - Sep 1994
Externally publishedYes

Fingerprint

Pneumocystis carinii
Introns
arginine
Arginine
introns
Catalytic RNA
Molecular Weight
peptides
RNA
molecular weight
drugs
Peptides
Acids
GIR1 ribozyme
acids
Enzymes
enzymes
Pharmaceutical Preparations
Proteins
proteins

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Agricultural and Biological Sciences (miscellaneous)
  • Applied Microbiology and Biotechnology
  • Microbiology

Cite this

Bidirectional effectors of a group I intron ribozyme from Pneumocystis carinii. / Liu, Y.; Leibowitz, Michael J.

In: The Journal of eukaryotic microbiology, Vol. 41, No. 5, 09.1994.

Research output: Contribution to journalArticle

@article{f5aa71b6764c4c57b7d3761fca4d5491,
title = "Bidirectional effectors of a group I intron ribozyme from Pneumocystis carinii.",
abstract = "The L-arginine acts stereoselectively on the Pc1.LSU nuclear group I intron of Pneumocystis carinii, competitively inhibiting the first step of the splicing reaction and stimulating the second step. A number of arginine-related compounds are more potent than L-arginine as stimulators and inhibitors. The most potent peptides tested are 10,000 times as effective as L-arginine in inhibiting ribozyme activity, and nearly 400 times as effective as stimulators. This phenomenon indicates that ribozymes, like protein enzymes, can interact with non-substrate low molecular weight compounds, and that non-nucleic acid agents might be developed as drugs acting on RNA targets.",
author = "Y. Liu and Leibowitz, {Michael J}",
year = "1994",
month = "9",
language = "English (US)",
volume = "41",
journal = "Journal of Eukaryotic Microbiology",
issn = "1066-5234",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Bidirectional effectors of a group I intron ribozyme from Pneumocystis carinii.

AU - Liu, Y.

AU - Leibowitz, Michael J

PY - 1994/9

Y1 - 1994/9

N2 - The L-arginine acts stereoselectively on the Pc1.LSU nuclear group I intron of Pneumocystis carinii, competitively inhibiting the first step of the splicing reaction and stimulating the second step. A number of arginine-related compounds are more potent than L-arginine as stimulators and inhibitors. The most potent peptides tested are 10,000 times as effective as L-arginine in inhibiting ribozyme activity, and nearly 400 times as effective as stimulators. This phenomenon indicates that ribozymes, like protein enzymes, can interact with non-substrate low molecular weight compounds, and that non-nucleic acid agents might be developed as drugs acting on RNA targets.

AB - The L-arginine acts stereoselectively on the Pc1.LSU nuclear group I intron of Pneumocystis carinii, competitively inhibiting the first step of the splicing reaction and stimulating the second step. A number of arginine-related compounds are more potent than L-arginine as stimulators and inhibitors. The most potent peptides tested are 10,000 times as effective as L-arginine in inhibiting ribozyme activity, and nearly 400 times as effective as stimulators. This phenomenon indicates that ribozymes, like protein enzymes, can interact with non-substrate low molecular weight compounds, and that non-nucleic acid agents might be developed as drugs acting on RNA targets.

UR - http://www.scopus.com/inward/record.url?scp=19244376922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244376922&partnerID=8YFLogxK

M3 - Article

VL - 41

JO - Journal of Eukaryotic Microbiology

JF - Journal of Eukaryotic Microbiology

SN - 1066-5234

IS - 5

ER -